Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-12-11 03:52
摘要：
YSCH-01, a recombinant oncolytic adenovirus, has shown significant anti-tumor efficacy against osteosarcoma in both patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models. The study reveals that YSCH-01 activates the type I interferon signaling pathway, contributing to its therapeutic effects. In vitro and in vivo experiments demonstrated dose-dependent cytotoxicity and tumor inhibition, positioning YSCH-01 as a promising candidate for osteosarcoma treatment. Further research is warranted to explore its clinical applications and optimize treatment protocols.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
YSCH-01 exhibited potent therapeutic effects with significant inhibition of osteosarcoma cell proliferation.
The study identified type I interferon signaling pathway as a candidate molecular marker.
In vivo experiments demonstrated significant tumor inhibition rates in both CDX and PDX models.
真实性检查
否
AI评分总结
YSCH-01, a recombinant oncolytic adenovirus, has shown significant anti-tumor efficacy against osteosarcoma in both patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models. The study reveals that YSCH-01 activates the type I interferon signaling pathway, contributing to its therapeutic effects. In vitro and in vivo experiments demonstrated dose-dependent cytotoxicity and tumor inhibition, positioning YSCH-01 as a promising candidate for osteosarcoma treatment. Further research is warranted to explore its clinical applications and optimize treatment protocols.